Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741194 · ClinicalTrials.gov registry record · Phase 2
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
A Phase 2 study, sponsored by Cerecin.
- Completed
- Registry status
- Phase 2
- Development phase
- 418
- Enrollment target
NCT01741194: Completed Phase 2 study, sponsored by Cerecin.
NCT01741194 is a Phase 2 study that has completed, run by Cerecin. The registered enrollment target is 418 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01741194, a Phase 2 study, has completed, sponsored by Cerecin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 418 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
Interventions
- DRUG Placebo
- DRUG AC-1204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01741194
The ClinicalTrials.gov registry entry for NCT01741194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerecin, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01741194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01741194 about?
NCT01741194 is a clinical study titled "AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext". This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT01741194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 418 participants. The study started on 2013-03. Estimated completion is 2017-04-14.
What interventions are being tested in trial NCT01741194?
The interventions under investigation include: Placebo (DRUG), AC-1204 (DRUG).
Who is sponsoring clinical trial NCT01741194?
This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.